Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, has been added to the Russell 2000® Index. The index measures the performance of the 2,000 largest U.S. companies based on total market capitalization. The Russell Investment Group recently reconstituted its indexes, and Russell 2000 membership went into effect at market close on June 24, 2011, and will remain in place for one year.
“Inclusion in the latest Russell 2000 Index recognizes CSI's growth and enhances our visibility among investors”
"Inclusion in the latest Russell 2000 Index recognizes CSI's growth and enhances our visibility among investors," said David L. Martin, CSI president and chief executive officer. "Within the last year, we launched our third-generation Stealth 360°™ Orbital PAD System with significant ease-of-use innovations, expanded our wealth of clinical data demonstrating our orbital technology's superior safety and effectiveness in treating peripheral arterial disease (PAD), and launched our pivotal trial for a coronary application in calcified lesions. Our progress on these fronts positions CSI for strong growth in both the PAD and large underserved coronary markets."
The Russell 2000 Index is constructed to provide a comprehensive, unbiased and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected.
Preventive PCI reduces cardiac event risks in patients with high-risk plaque